What is the 13F Pro Quality Score for ABBV?

13F Pro ranks AbbVie Inc. (ABBV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABBV's current score at https://13fpro.ai/research/ABBV (free sign-up required for the full ranking).

Which hedge funds own the most ABBV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ABBV include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ABBV as soon as new 13F filings post.

Where does 13F Pro source ABBV data?

All AbbVie Inc. fundamentals and ownership data come directly from SEC EDGAR. AbbVie Inc. files with the SEC under CIK 1551152. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABBV in?

AbbVie Inc. (ABBV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABBV research updated on 13F Pro?

ABBV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AbbVie Inc.(ABBV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1551152 ABBV stock profile & AI dashboard →

13F Pro Quality Score

59.3/100

Rank #933 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

56.2/100

Profitability

38.6/100

Balance Sheet

53.7/100

Earnings Quality

16.0/100

Free Cash Flow

84.4/100

Institutional Flow

37.3/100

Revenue Scale

97.7/100

Dilution Risk

46.0/100

ABBV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AbbVie Inc. (ABBV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABBV at 59.3/100 on a 32-signal composite quality model, placing it at rank #933 of 2,879 stocks — the top half of the AI-ranked universe. ABBV scores in the top quartile across revenue scale (97.7), free cash flow (84.4). Areas of concern include earnings quality (16.0) and institutional flow (37.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AbbVie Inc. reports quarterly revenue of $15.0B, net income of $695.0M, an operating margin of 26.6%. Top institutional holders of ABBV by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABBV trades on the NYSE exchange and files with the SEC under CIK 1551152. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABBV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbbVie Inc. directly from SEC EDGAR. AbbVie Inc.'s 13F Pro composite quality score has ranged between 54 and 82 since 2021, currently 59.3 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about AbbVie Inc.

Quirks, history, and lore behind ABBV — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. pharmaceutical company · large-cap · listed on the NYSE · headquartered in Illinois.
2
The Numbers
Annual revenue around $55 billion, built heavily on a single blockbuster drug that for years was the world's best-selling medicine by revenue.
3
The History
Spun off from a major pharmaceutical parent in 2013, it was handed the crown jewel drug and told to go make its own fortune — which it very much did.
4
The Secret
Its R&D pipeline leans hard into immunology, oncology, and neuroscience, and it has spent aggressively on acquisitions to reduce its dependence on that one famous drug.
5
The Lore
When its flagship drug's patents began expiring, the company fought biosimilar rivals with a patent thicket so vast it became a case study in pharmaceutical legal strategy — and a congressional punching bag.
6
The Giveaway
If your joints ache, you've probably seen the ads: Humira, the rheumatoid-arthritis injection that single-handedly redefined what a blockbuster drug could earn.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$15.0B

Net Income

Q1 2026

$695.0M

Free Cash Flow

Q1 2026

$3.6B

Operating Margin

Q1 2026

26.6%

ROIC

Q1 2026

6.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.6% YoY

$61.16BFY 2025

FY22 $58.05BFY23 $54.32BFY24 $56.33BFY25 $61.16B

Net Income

-1.2% YoY

$4.23BFY 2025

FY22 $11.84BFY23 $4.86BFY24 $4.28BFY25 $4.23B

Operating Income

+65.0% YoY

$15.07BFY 2025

FY22 $18.12BFY23 $12.76BFY24 $9.14BFY25 $15.07B

EPS (Diluted)

-1.3% YoY

$2.36FY 2025

FY22 $6.63FY23 $2.72FY24 $2.39FY25 $2.36

Total Assets

-0.9% YoY

$133.96BFY 2025

FY22 $138.81BFY23 $134.71BFY24 $135.16BFY25 $133.96B

Total Debt

-0.8% YoY

$73.06BFY 2025

FY22 $67.26BFY23 $66.44BFY24 $73.64BFY25 $73.06B

Op. Cash Flow

+1.2% YoY

$19.03BFY 2025

FY22 $24.94BFY23 $22.84BFY24 $18.81BFY25 $19.03B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$61.16B +8.6%	$56.33B +3.7%	$54.32B -6.4%	$58.05B +3.3%	$56.20B +22.7%	$45.80B
Net Income	$4.23B -1.2%	$4.28B -12.0%	$4.86B -58.9%	$11.84B +2.5%	$11.54B +150.0%	$4.62B
Operating Income	$15.07B +65.0%	$9.14B -28.4%	$12.76B -29.6%	$18.12B +1.1%	$17.92B +57.7%	$11.36B
EPS (Diluted)	$2.36 -1.3%	$2.39 -12.1%	$2.72 -59.0%	$6.63 +2.8%	$6.45 +137.1%	$2.72
Total Assets	$133.96B -0.9%	$135.16B +0.3%	$134.71B -2.9%	$138.81B -5.3%	$146.53B -2.7%	$150.56B
Total Debt	$73.06B -0.8%	$73.64B +10.9%	$66.44B -1.2%	$67.26B -24.0%	$88.46B -5.3%	$93.45B
Operating Cash Flow	$19.03B +1.2%	$18.81B -17.7%	$22.84B -8.4%	$24.94B +9.5%	$22.78B +29.5%	$17.59B

AI Insight: ABBV Financial Trends

Revenue growth stabilizes near 16B but profitability remains volatile; equity has turned deeply negative.

• Revenue grew from 14.5B in Q2 2024 to 15.0B in Q1 2026, posting 3.8% CAGR despite Q4 2024 operational loss.

• Operating income recovered to 3.99B in Q1 2026 from 1.9B in Q3 2025, signaling margin stabilization.

• Operating cash flow remains robust at 3.8B–7.0B quarterly, averaging 5.1B over last eight quarters.

⚠ Equity deteriorated from 6.8B in Q2 2024 to -6.7B in Q1 2026; negative since Q2 2025, signaling capital structure stress.

⚠ Net income highly volatile: -22M in Q4 2024, 186M in Q3 2025, 1.8B in Q4 2025; Q1 2026 at 695M reflects ongoing instability.

⚠ Total debt stable 68.7B–73.7B despite negative equity; leverage metrics deteriorating materially.

AI Insight: ABBV Ratio Trends

ROIC recovered to 24.1% in Q1 2026 after Q3 2025 collapse, but operating margin deteriorated to 26.6% from 27.3% prior quarter.

• ROIC rebounded sharply from 11.5% in Q3 2025 to 24.1% in Q1 2026, signaling operational recovery post-disruption.

• Operating margin declined to 26.6% in Q1 2026 from 27.3% in Q4 2025; NPM fell to 4.6% from 10.9%.

• ROA compressed to 2.0% in Q1 2026 from 5.4% in Q4 2025, lowest since Q2 2024's 3.9%.

⚠ Q3 2025 saw near-total profitability collapse (OpMargin -9.9%, NPM -0.1%); root cause and recurrence risk unclear.

⚠ Net profit margin volatility (10.9% → 1.2% → 10.9% → 4.6% across last four quarters) suggests earnings quality concerns.

Get alerted when ABBV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AbbVie Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABBV

BlackRock, Inc.
$32.8B150,698,125 sh
VANGUARD CAPITAL MANAGEMENT LLC
$25.0B114,880,324 sh
STATE STREET CORP
$17.7B81,217,516 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$10.8B49,523,078 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.1B46,737,581 sh
MORGAN STANLEY
$8.3B38,016,774 sh
Capital Research Global Investors
$6.8B31,254,786 sh
BANK OF AMERICA CORP /DE/
$5.2B23,936,943 sh
FMR LLC
$4.7B21,762,703 sh
NORTHERN TRUST CORP
$4.6B21,211,382 sh

Fund	Value	Shares
BlackRock, Inc.	$32.8B	150,698,125
VANGUARD CAPITAL MANAGEMENT LLC	$25.0B	114,880,324
STATE STREET CORP	$17.7B	81,217,516
VANGUARD PORTFOLIO MANAGEMENT LLC	$10.8B	49,523,078
GEODE CAPITAL MANAGEMENT, LLC	$10.1B	46,737,581
MORGAN STANLEY	$8.3B	38,016,774
Capital Research Global Investors	$6.8B	31,254,786
BANK OF AMERICA CORP /DE/	$5.2B	23,936,943
FMR LLC	$4.7B	21,762,703
NORTHERN TRUST CORP	$4.6B	21,211,382

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

ABT

ABBOTT LABORATORIES

Put ABBV on your watchlist

Track score changes the day AbbVie Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABBV a good stock to buy?

13F Pro's AI-powered analysis of AbbVie Inc. (ABBV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABBV are available on the ABBV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABBV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABBV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AbbVie Inc.'s investment landscape.